Change in hemoglobin trajectory and darbepoetin dose approaching end-stage renal disease: data from the trial to reduce cardiovascular events with aranesp therapy trial
Journal article
Mc Causland, Finnian R., Claggett, Brian L., Pfeffer, Marc A., Burdmann, Emmanuel A., Eckardt, Kai Uwe, Levey, Andrew S., McMurray, John, Remuzzi, Giuseppe, Singh, Ajay K., Solomon, Scott, Toto, Robert D. and Parfrey, Patrick. (2017). Change in hemoglobin trajectory and darbepoetin dose approaching end-stage renal disease: data from the trial to reduce cardiovascular events with aranesp therapy trial. American Journal of Nephrology. 46(6), pp. 488 - 497. https://doi.org/10.1159/000485326
Authors | Mc Causland, Finnian R., Claggett, Brian L., Pfeffer, Marc A., Burdmann, Emmanuel A., Eckardt, Kai Uwe, Levey, Andrew S., McMurray, John, Remuzzi, Giuseppe, Singh, Ajay K., Solomon, Scott, Toto, Robert D. and Parfrey, Patrick |
---|---|
Abstract | Background: |
Keywords | Anemia; Hemoglobin; C-reactive protein; End-stage renal disease Type 2 diabetes mellitus; Chronic kidney disease |
Year | 2017 |
Journal | American Journal of Nephrology |
Journal citation | 46 (6), pp. 488 - 497 |
Publisher | S. Karger AG |
ISSN | 0250-8095 |
Digital Object Identifier (DOI) | https://doi.org/10.1159/000485326 |
Scopus EID | 2-s2.0-85038117726 |
Page range | 488 - 497 |
Research Group | Mary MacKillop Institute for Health Research |
Publisher's version | File Access Level Controlled |
Place of publication | Switzerland |
Editors | G. L. Bakris |
https://acuresearchbank.acu.edu.au/item/89yy0/change-in-hemoglobin-trajectory-and-darbepoetin-dose-approaching-end-stage-renal-disease-data-from-the-trial-to-reduce-cardiovascular-events-with-aranesp-therapy-trial
Restricted files
Publisher's version
91
total views0
total downloads0
views this month0
downloads this month